TIDMSEED
Seed Innovations Limited
24 January 2024
24 January 2024
SEED Innovations Limited
("SEED" or the "Company")
Investee Company Update: Avextra AG
SEED Innovations Ltd, the AIM-quoted company investment company
providing shareholders with exposure to early-stage health,
wellness and medical cannabis companies to which, in normal
circumstances, they have limited access to , is pleased to note the
announcement released by its portfolio company, Avextra AG
('Avextra'), a German-based, European vertically integrated medical
cannabis company.
SEED remains a holder of 2,242 shares in Avextra representing
approximately 3% of Avextra on a fully diluted basis.
The following extract from the announcement is set out without
material changes or adjustments and the announcement in full can be
accessed from the following link:
https://www.globenewswire.com/news-release/2024/01/23/2813771/0/en/German-Pain-Association-DGS-and-Pharmaceutical-Company-Avextra-Join-Forces-to-Launch-Their-New-Study-OCEAN.html
Start of Avextra AG announcement:
23 January 2024
German Pain Association (DGS) and Pharmaceutical Company
Avextra
Join Forces to Launch Their New Study OCEAN
Highlights
-- Avextra, the German pharmaceutical company focused on
Cannabis-Based Medicines (CBM) and the German Pain Association
(DGS), the leading physicians' society dedicated to chronic pain
therapy, jointly announces their collaboration to support patients
suffering from Chemotherapy-induced neuropathic pain (CINP).
-- CINP causes persistent pain and numbness symptoms in 60-80%
of oncology patients undergoing cancer treatments, significantly
impacting their quality of life.
-- For the next 18 months the two organisations aim to
investigate the efficacy and safety of Avextra's THC/CBD
full-spectrum extract in approximately 400 CINP patients in over 20
DGS centres throughout Germany in a real-world environment.
-- OCEAN marks the next project in Avextra's Alliance for
Evidence-based Cannabis Medicine dedicated to conducting studies
within the framework of exclusive partnerships using diverse
galenic forms to address indications with significant unmet patient
need.
BENSHEIM, Germany, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Avextra AG
("Avextra" or the "Company"), a leading European
vertically-integrated manufacturer and developer of pharmaceutical
cannabis-based medicines (CBMs) located in Germany, is proud to
announce a joint study with the German Pain Association (DGS)
focused on Chemotherapy-induced neuropathic pain (CINP). The study
which is being conducted under the name of OCEAN is the next
initiative as part of Avextra's Alliance for Evidence-based
Cannabis Medicine. Initial studies indicate that cannabis-based
medicine (CBMs) could be a promising indication for neuropathic
pain conditions, including CINP. However, as is often the case in
the field of cannabis medicine, reliable evidence is lacking for
this vulnerable patient population. Avextra is proud to collaborate
with the German Pain Association (DGS) on their OCEAN study and
address the research gap.
CINP is an independent pain disorder resulting from the toxic
peripheral nerve damage caused by chemotherapy agents in the course
of the treatment. The real-world study aims to investigate whether
a full-spectrum cannabinoid extract could be a suitable therapeutic
addition to alleviate the symptom burden of chemotherapy
patients.
OCEAN is a prospective 12-week parallel group observational
study utilising Avextra's own balanced 10:10 (THC:CBD) Cannabis
extract conducted under real-world conditions with 400 adults
suffering from CINP. OCEAN will evaluate a number of factors
including pain intensity, pain-related impairments, sleep quality
and the phenotypes of neuropathic pain. Upon completion, the study
results will contribute to a more precise understanding of the
treatment requirements for the patients affected, offering valuable
insights to inform the design of a future Phase III clinical
trial.
"OCEAN is a unique and promising opportunity to gain valuable
patient data aimed to improve the quality of life for CINP
patients. We are delighted to partner with the DGS to collect
real-world evidence in Germany throughout this study. This
initiative is an important part of our Alliance for Evidence-Based
Cannabis Medicine, with a significant goal of developing
cannabis-based medicines tailored to address specific indications,
ultimately providing symptom relief to a broader patient
population," explains Dr. Bernhard Babel, CEO of Avextra.
The OCEAN study is now underway. "Our association has gathered
valuable experience in treating chronic pain patients with
cannabis-based medicines. Together with Avextra, we aim to
investigate the efficacy and safety of a THC/CBD full-spectrum
extract 10mg/10mg in comparison to a non-cannabis-based comparative
therapy amongst the large patient population suffering from
neuropathy as a result of chemotherapy. This prospective, 12-week
parallel group study is designed as a non-interventional approach,"
states DGS President, Dr. med. Dipl. Lic. Psych. Johannes
Horlemann. "There is a large unmet need for neuropathic pain
therapy amongst patients after undergoing chemotherapy. Because
success of the chemotherapy is often the main focus, patients often
do not address their pain symptoms in subsequent physician
consultations. Standard medications for neuropathic pain provide
little or no relief. A study is therefore essential to determine
how pain and the accompanying symptoms can be improved by a THC-CBD
full-spectrum extract. We are looking forward to the results,"
summarises Dr. med. Dipl. Lic. Psych. Johannes Horlemann.
Avextra is focused on creating cannabis-based medicines "CBMs"
that will gather the necessary evidence to support the use of
unregistered CBMs and expedite the development of Registered
Cannabis-based Medicines. The Company is committed to transparency,
and as such, the trials and study results will be shared with the
scientific community and regulatory authorities, contributing to
the collective knowledge of cannabinoid-based therapies. The
company is dedicated to working in collaboration with the medical
community, regulators, and other stakeholders to drive
evidence-based innovation forward.
End of Avextra AG announcement:
-Ends-
For further information on the Company please visit: www.seedinnovations.co or contact:
Ed McDermott SEED Innovations E: info@seedinnovations.co
Lance de Ltd
Jersey
James Biddle Beaumont Cornish T: (0)20 7628 3396
Roland Cornish Limited,
Nomad
------------------- -------------------------------
Isabella Shard Capital T: (0)20 7186 9927
Pierre Partners LLP
Damon Heath Broker
------------------- -------------------------------
Ana Ribeiro St Brides Partners E: seed@stbridespartners.co.uk
Isabelle Ltd,
Morris Financial PR
------------------- -------------------------------
Notes
Seed Innovations Ltd
SEED Innovations is an AIM quoted investment company focused
primarily on disruptive high growth life sciences and technology
businesses particularly within the medical cannabis arena. The
Company's strategy is to identify early-stage opportunities that
have an upcoming investment catalyst and grow its portfolio in
terms of value whilst limiting the number of investee companies to
a level where relevant time can be devoted to each.
About Avextra AG
Avextra is one of Europe's leading vertically integrated
suppliers of high-quality cannabis-based medicines. Founded in 2019
and based out of Germany, the company focuses on the production of
precisely formulated cannabis-based medicines. Avextra controls the
entire value chain - from cultivation in Portugal to EU-GMP
certified extraction and manufacturing in Germany. Avextra operates
across continental Europe through an expansive distribution network
of multiple channels and assets strategically developed for these
key markets.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFXLLLZFLZBBQ
(END) Dow Jones Newswires
January 24, 2024 02:00 ET (07:00 GMT)
Grafico Azioni Seed Innovations (LSE:SEED)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Seed Innovations (LSE:SEED)
Storico
Da Set 2023 a Set 2024